

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation

先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1302)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of LifeTech Scientific Corporation (the “**Company**”) hereby announces that Mr. FU Feng has been appointed as a non-executive Director with effect from 28 August 2019.

The board of directors (the “**Board**”) of LifeTech Scientific Corporation (the “**Company**”) hereby announces that Mr. FU Feng (“**Mr. Fu**”) has been appointed as a non-executive Director with effect from 28 August 2019.

Mr. Fu, aged 49, holds a Bachelor’s degree in International Finance from East China Normal University (華東師範大學) and a Master of Business Administration from the University of British Columbia (英屬哥倫比亞大學). Mr. Fu was admitted as a Chartered Financial Analyst of the CFA Institute in 2003. Mr. Fu has over 16 years of experience in financial investments and transactions, covering companies in various stages of growth and expansion. Mr. Fu is the managing director and head of healthcare fund at China Everbright Limited. From 2013 to 2016, Mr. Fu served as the head of healthcare investment and the managing director at both the Hillhouse Capital and TPG Growth Capital. Mr. Fu served as the head of healthcare investment and the executive director at FountainVest Partners from 2008 to 2013. He was the national sales director of Sanjiu Pharmaceutical Co. Ltd. from 1992 to 1999 and was responsible for managing exclusive agency business with multinational pharmaceutical companies.

Save as disclosed in this announcement, Mr. Fu does not hold any other position in the Group and does not have any other major appointments and professional qualifications, and did not hold any directorships in public companies of which the securities are listed on any securities market in Hong Kong or overseas in the last three years preceding the date of his appointment. Mr. Fu does not have any relationship with any directors, senior management and substantial shareholders of the Company.

Mr. Fu has entered into an appointment letter with the Company for a term of three years commencing from 28 August 2019, which may be terminated by the Company giving written notice under certain situations as provided under the appointment letter. Mr. Fu's tenure as a non-executive Director is subject to retirement by rotation and re-election in accordance with the articles of association of the Company. Mr. Fu is not entitled to any emoluments under the director appointment letter.

As at the date of this announcement, Mr. Fu does not have any interest in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save as disclosed above, there is no other information that is required to be disclosed under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters in relation to the appointment of Mr. Fu that need to be brought to the attention of the shareholders of the Company.

The Board would like to extend a warm welcome to Mr. Fu for joining as a member of the Board.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui

Executive Director, Chairman and Chief Executive Officer

28 August 2019, Hong Kong

As at the date hereof, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive directors of the Company; Mr. JIANG Feng and Mr. FU Feng being non-executive directors of the Company; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive directors of the Company.